What is the latest published HBAN stock rating?

Huntington Bancshares Incorporated is shown with Strong Buy in the latest published report, analyzed 2026-10-05. The hub links directly to the full analysis surface where the dated rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full HBAN analysis?

The full latest published report, analyzed 2026-10-05, lives at /stocks/HBAN/analysis. The bare ticker page summarizes that read and links to each analysis tab; earlier editions remain under /analysis/archive.

What fair value is used for HBAN?

The latest published report analyzed 2026-10-05 gives HBAN a fair value of USD 21 and a potential value of USD 30. These are dated research outputs, not live market prices; review the valuation assumptions, sensitivity analysis, and material risks before making a decision.

How often is the HBAN page updated?

The hub selects the latest published stock report regardless of age and displays its analysis date (2026-10-05). Separately sourced market data is labeled with its own recorded timestamp and is never inferred from the report.

HBAN Stock: Fundamentals & Analysis | StockMarketAgent.AI

ログイン Start free

Huntington Bancshares Incorporated (HBAN)

NASDAQ: HBAN · USD

—

StockMarketAgent Research · Analyzed 2026-10-05

Our latest published analysis: HBAN rated Strong Buy

Huntington Bancshares Incorporated's published Strong Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.

Fair value

$20.8 / share

Potential value

$30.1 / share

Upside to FV

+35.8%

Moat

6.5/10

Narrow

Read full analysis →View archive · 24mo

9-phase methodology · same model in each published edition

Market cap	$31.0B
P/E (forward)	8.6x

Market data

Price

Recent price action with selectable time range.

Financial snapshot

P/E (forward): 8.6x
Market cap: $31.0B

Item	P1	P2	P3	P4	P5	Trend
Period	2021-12-31	2022-12-31	2023-12-31	2024-12-31	2025-12-31	Trend
Revenue	$1.11B	$1.32B	$1.40B	$1.47B	$1.56B	+8.8%
Gross profit	$5.97B	$6.97B	$6.90B	$6.97B	$7.70B	+6.6%
Operating income	$1.59B	$2.76B	$2.38B	$2.40B	$2.69B	+14.0%
Net income	$1.30B	$2.24B	$1.95B	$1.94B	$2.21B	+14.3%
EPS (diluted)	$0.90	$1.45	$1.24	$1.22	$1.39	+11.5%
EBITDA	$1.98B	$3.25B	$3.18B	$3.03B	$3.45B	+14.9%
R&D	—	—	—	—	—	—
SG&A	$2.39B	$2.47B	$2.83B	$2.82B	$3.50B	+10.0%

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
ABBV	AbbVie Inc.	—	—	—	—	—	—	売り
ABT	Abbott Laboratories	—	—	—	—	—	—	縮小
ACN	Accenture plc	—	—	—	—	—	—	ホールド
ACGL	Arch Capital Group Ltd.	—	—	—	—	—	—	強い買い
AIG	American International Group Inc.	—	—	—	—	—	—	強い買い
AIZ	Assurant, Inc.	—	—	—	—	—	—	ホールド

Base and Bull scenarios

Base60%

Price target

$20.81

+35.7% from spot

The base case reflects orderly post-merger integration of Cadence and Veritex following the completion of the core systems conversion in mid-June 2026. Earning asset scale drives net interest income expansion, while fee platforms in payments, wealth management, and capital markets deliver steady growth. Synergies reduce operating expense intensity, allowing operating margins to normalize from 36.5% toward 40.5% by FY2029. Credit losses remain contained near historical norms with net charge-offs averaging 0.25%-0.30%, supporting disciplined capital distribution via dividends and opportunistic share buybacks.

House forecast EPS expands from $1.69 in FY2026 to $1.77 in FY2027 and $2.08 by FY2030
Operating margin expands from 36.5% in FY2026 to 40.5% in FY2029-FY2030 as integration synergies materialize
Cost of equity remains moderate at 8.468% with a 10.0x terminal P/E multiple
Reinvestment rate maintained at 8.0% of NOPAT with an effective tax rate of 18.1%

Bull20%

Price target

$30.13

+96.5% from spot

In the bull scenario, Huntington capitalizes aggressively on market share opportunities across high-growth Southeast markets acquired through Cadence and Texas operations from Veritex. Rapid cross-selling of capital markets, payments, and wealth products drives superior noninterest revenue expansion. Synergy realization exceeds management targets, driving the efficiency ratio below 55% and expanding ROTCE above 18%. Benign credit trends and expanding pre-provision net revenue enable accelerated share repurchases while sustaining healthy dividend growth.

EPS growth accelerates to 10% in Year 1, 7% in Year 2, and 5% in Year 3
Net interest margin expands above 3.35% driven by rapid deposit growth in Southeast expansion markets and lower funding costs
Fee income from advisory, payments, and wealth accelerates beyond double-digit growth rates
Annualized net charge-offs remain benign below 0.20% with CET1 ratio rising above 10.5%

Sensitivity: Ke × terminal growth

The highlighted cell is Fair value when every assumption sits at its base level ($20.81). Each row and column shows what Fair value becomes when one assumption moves.

Ke ↓ / g →	2.0%	2.3%	2.5%	2.8%	3.0%
7.5%	$23.0	$23.9	$24.9	$26.0	$27.2
8.0%	$21.1	$21.9	$22.7	$23.6	$24.5
8.5%	$19.5	$20.1	$20.8	$21.5	$22.3
9.0%	$18.1	$18.7	$19.2	$19.8	$20.5
9.5%	$16.9	$17.4	$17.9	$18.4	$18.9

Scorecard

Published factor rows and weighted composite

Valuation8.5

Management7.5

Balance Sheet5.0

Profitability6.5

Revenue Growth9.0

Risk Assessment6.0

Competitive Moat6.5

Earnings Quality6.0

Capital Efficiency4.0

Weighted composite

6.6/10

Above average

Category	Score	Reading
Valuation	8.5
Management	7.5
Balance Sheet	5.0
Profitability	6.5
Revenue Growth	9.0
Risk Assessment	6.0
Competitive Moat	6.5
Earnings Quality	6.0
Capital Efficiency	4.0

レーティング履歴

各月に公開されたリサーチ版が示したレーティングです。レーティングは分析時点の株価を公正価値と比較したもので、判断が当たったかどうかの記録ではありません。

年	1月	2月	3月	4月	5月	6月	7月	8月	9月	10月	11月	12月
2026

Huntington Bancshares Incorporated (HBAN)

Our latest published analysis: HBAN rated Strong Buy

Price

Financial snapshot

Fair-value bridge

Latest news · HBAN

Valuation

Base and Bull scenarios

Sensitivity: Ke × terminal growth

Scorecard

Next earnings

Sector percentile context

Deeper analysis on HBAN

Frequently asked questions

レーティング履歴